文献速递肝病消化道肿瘤与早癌

强制6个月等待期对肝细胞癌患者等待名单及移植结局的影响

Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
PubMed 文献 · Hepatology · 2020-10-22

本研究基于UNOS登记数据,比较强制6个月等待期实施前后肝细胞癌(HCC)肝移植候选者的等待名单及移植后结局。实施后早期移植概率下降(42.0% vs 6.3%),但6个月等待名单死亡率/脱落率降低(1.2% vs 4.1%),区域差异缩小但未消除,移植后死亡率及米兰标准符合率无变化。

要点

  • 强制6个月等待期使HCC患者早期移植概率从42.0%降至6.3%(P<0.001)。
  • 等待期政策使6个月等待名单死亡率/脱落率从4.1%降至1.2%(P<0.001)。
  • 区域移植机会差异缩小但未消除,高MELD评分区域获益更显著。

核心结论

  • HCC政策变更与等待名单死亡率/脱落率降低及移植概率增加相关。
  • 政策有助于减少但未消除移植机会的区域差异,且未影响移植后结局。

研究设计与样本

  • 回顾性队列研究,使用UNOS登记数据,比较政策实施前组(2013年1月1日至2015年10月7日,n=4,814)与实施后组(2015年10月8日至2018年6月30日,n=3,287)。

主要发现

  • 实施前组移植后前6个月移植概率为42.0%,实施后组为6.3%(P<0.001)。
  • 实施后组6个月等待名单死亡率/脱落率为1.2%,实施前组为4.1%(P<0.001)。
  • 条件等待名单死亡率/脱落率下降及移植概率增加在所有区域组中均出现,但高和中MELD评分区域获益更明显。
  • 等待名单死亡率/脱落率下降仅在高MELD评分区域组中显著(P<0.001)。
  • 移植后死亡率或移植肝符合米兰标准的比例无变化。

关键数值与推荐

  • UNOS政策强制HCC肝移植候选者等待6个月后才授予例外评分。
  • UNOS区域按移植时MELD评分分为三组:低评分区(3、10、11区)、中评分区(1、2、6、8、9区)、高评分区(4、5、7区)。

临床怎么用

  • 临床医生在为HCC患者制定移植计划时,应考虑强制6个月等待期对早期移植概率的降低及对等待名单脱落率的改善。
  • 政策实施后区域间移植机会差异仍存在,需关注高MELD评分区域的获益更显著。
  • 移植后结局未受政策影响,可据此咨询患者。

局限性

  • 研究为回顾性登记数据分析,可能存在未测量混杂因素。
  • 未报告政策对移植后长期结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Organ Procurement and Transplantation Network/United Network for Organ Sharing (OPTN/UNOS) policy mandates a 6-month waiting period before exception scores are granted to liver transplant candidates with hepatocellular carcinoma (HCC). This study aims to evaluate waitlist and posttransplant outcomes in patients with HCC, before and after implementation of the 6-month waiting rule. APPROACH AND RESULTS: We examined two groups from the UNOS registry: Group 1 (pre-6-month rule) consisted of patients registered as transplant candidates with HCC from January 1, 2013, to October 7, 2015 (n = 4,814); group 2 (post-6-month rule) consisted of patients registered from October 8, 2015, to June 30, 2018 (n = 3,287). As expected, the transplant probability was higher in the first 6 months after listing in group 1 than group 2 at 42.0% versus 6.3% (P < 0.001). However, the 6-month waitlist mortality/dropout rate was lower in group 2 at 1.2% than group 1 at 4.1% (P < 0.001). To assess regional parity of transplant, UNOS regions were categorized into three groups based on Model for End-Stage Liver Disease score at transplant: lower-score (regions 3, 10, and 11), middle-score (1, 2, 6, 8, and 9), and higher-score region groups (4, 5, and 7). Outcomes were compared from the time exception points were given, which we defined as conditional waitlist outcomes. Conditional waitlist mortality/dropout decreased, and transplant probability increased in all region groups, but the benefits of the policy were more pronounced in the higher and middle-score groups, compared with the lower-score group. The decline in waitlist mortality/dropout was only significant in the high Model for End-Stage Liver Disease group (P < 0.001). No effect was observed on posttransplant mortality or percent of patients within Milan criteria on explant. CONCLUSIONS: The HCC policy change was associated with decreased waitlist mortality/dropout and increased transplant probability. The policy helped to decrease but did not eliminate regional disparities in transplant opportunity without an effect on posttransplant outcomes.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Nagai S, Kitajima T, Yeddula S, et al. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma. Hepatology. 2020. PMID: 32157711. doi:10.1002/hep.31223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。